Search results for "MESH: Antiviral Agents"

showing 3 items of 3 documents

Smoking trends among adolescents from 1990 to 2002 in ten European countries and Canada.

2006

Abstract Background Daily smoking adolescents are a public health problem as they are more likely to become adult smokers and to develop smoking-related health problems later on in their lives. Methods The study is part of the four-yearly, cross-national Health Behaviour in School-aged Children study, a school-based survey on a nationally representative sample using a standardised methodology. Data of 4 survey periods are available (1990–2002). Gender-specific daily smoking trends among 14–15 year olds are examined using logistic regressions. Sex ratios are calculated for each survey period and country. Interaction effects between period and gender are examined. Results Daily smoking preval…

Cross-Cultural ComparisonMaleMESH: Antiviral Agentsmedicine.medical_specialtyCanadaAdolescentMESH: SchoolsCross-sectional studyHealth BehaviorPsychological interventionLogistic regressionWorld Health OrganizationRisk-TakingMESH: Computer SimulationEnvironmental healthSurveys and QuestionnairesEpidemiologymedicinePrevalenceHumansSex DistributionMESH: Disease OutbreaksMESH: OrthomyxoviridaeSchoolsMESH: Humansbusiness.industrylcsh:Public aspects of medicinePublic healthMESH: Influenza HumanSmokingPublic Health Environmental and Occupational Healthlcsh:RA1-1270MESH: NeuraminidaseMESH: Mass ImmunizationCross-cultural studiesHealth SurveysEuropeCross-Sectional StudiesAdolescent Behavior[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieBiostatisticsbusinessMESH: QuarantineSex ratioMESH: Models StatisticalResearch Article
researchProduct

Patients With Isolated Hepatitis B Core Antibody: Has the Time Come to Vaccinate?

2017

International audience

Microbiology (medical)MESH: Antiviral AgentsMESH: Hepatitis B ChronicMEDLINEMESH: Hepatitis B Core AntigensAntiviral Agents03 medical and health sciences0302 clinical medicineHepatitis B ChronicmedicineHumansHepatitis B Vaccines030212 general & internal medicineHepatitis B AntibodiesMESH: Hepatitis B AntibodiesMESH: Hepatitis B VaccinesMESH: Humansbusiness.industryHepatitis Bmedicine.diseaseVirologyHepatitis B Core AntigensHepatitis b core antibodyMESH: DNA ViralInfectious Diseases[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieImmunologyDNA Viral030211 gastroenterology & hepatology[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusiness
researchProduct

Factors that predict response of patients with hepatitis C virus infection to boceprevir

2012

Background & Aims Little is known about factors associated with a sustained virologic response (SVR) among patients with hepatitis C virus (HCV) infection to treatment with protease inhibitors. Methods Previously untreated patients (from the Serine Protease Inhibitor Therapy 2 [SPRINT-2] trial) and those who did not respond to prior therapy (from the Retreatment with HCV Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol 2 [RESPOND-2] trial) received either a combination of peginterferon and ribavirin for 48 weeks or boceprevir, peginterferon, and ribavirin (triple therapy) after 4 weeks of peginterferon and ribavirin (total treatment duration, 28–48 wk). A good response to interfer…

MaleCirrhosisMESH: Logistic ModelsHepacivirusMESH: Risk AssessmentGastroenterologyPolyethylene GlycolsMESH: Recombinant ProteinsMESH: Genotype0302 clinical medicineOdds RatioProspective StudiesMESH: Treatment OutcomeResponse to Therapy0303 health sciencesMESH: Polymorphism Single NucleotideGastroenterologyvirus diseases3. Good healthMESH: RNA ViralHCVDrug Therapy Combination030211 gastroenterology & hepatologyClinical Trial; Genetic; Prognostic Factors; Response to Therapy; Adult; Antiviral Agents; Biomarkers; Canada; Drug Therapy Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interleukins; Logistic Models; Male; Multivariate Analysis; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism Single Nucleotide; Proline; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States; Viral Load; GastroenterologyViral loadmedicine.medical_specialtyMESH: InterleukinsGenotypeProlineInterferon alpha-2MESH: PhenotypeAntiviral AgentsRisk Assessment03 medical and health sciencesDrug TherapyGeneticMESH: RibavirinMESH: CanadaBoceprevirHumansPolymorphismMESH: ProlineMESH: HumansPrognostic FactorsInterleukinsMESH: AdultOdds ratiomedicine.diseaseUnited Statesdigestive system diseasesClinical trialLogistic ModelschemistryImmunologyMESH: FemaleBiomarkersTime Factorsmedicine.disease_causechemistry.chemical_compoundRisk FactorsInterferonMESH: Risk FactorsMESH: HepacivirusViralSingle NucleotideViral LoadHepatitis CClinical TrialRecombinant ProteinsEuropePhenotypeTreatment OutcomeCombinationRNA ViralFemaleMESH: Interferon-alphaMESH: Viral Loadmedicine.drugAdultMESH: Antiviral AgentsCanadaHepatitis C virusPolymorphism Single NucleotideMESH: Multivariate AnalysisInternal medicineRibavirinmedicineMESH: United States030304 developmental biologyMESH: Hepatitis CHepatologybusiness.industryRibavirinMESH: Time FactorsMESH: Biological MarkersInterferon-alpha[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Prospective StudiesMESH: MaleMESH: Odds RatioMESH: Drug Therapy CombinationMESH: Polyethylene GlycolsMultivariate AnalysisRNAInterferonsMESH: Europebusiness
researchProduct